AstraZeneca's anti-diabetic drug gets additional indication approval for heart failure treatment in India financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
DCGI okays AstraZeneca drug for treatment of heart failure in adults gujaratsamachar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gujaratsamachar.com Daily Mail and Mail on Sunday newspapers.
New Delhi, July 24 (IANS) The Drugs Controller General of India (DGCI) on Monday granted extended indication approval to AstraZeneca India’s Dapagliflozin in
The Drugs Controller General of India (DGCI) on Monday granted extended indication approval to AstraZeneca India's Dapagliflozin in the treatment of heart failure in adults.Dapagliflozin is already approved for heart failure patients with .
The Central Drugs Standard Control Organisation (CDSCO) has approved AstraZeneca Pharma India's liver cancer drug Tremelimumab Concentrate to be administered intravenously, the company said on Thursday.